GSK plc announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved a regulatory application to extend the indication of Arexvy (respiratory syncytial virus vaccine, recombinant ...

Moderna, Inc.'s stock plummets as challenges mount, including vaccine skepticism, competitive pressures, and the RFK ...

Current health news highlights a planned IPO by Medline Industries aiming to exceed $5 billion, a second Australian death from methanol poisoning in Laos, GSK's RSV vaccine approval in Japan, and ...

The company is pharmaceutical giant GSK (LSE: GSK) and it’s taken a real beating lately. I’ve seen that at first hand, ...

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price an opportunity ...

GSK said on Friday that its respiratory syncytial virus (RSV) vaccine has received approval in Japan for expanded use in ...

Global healthcare markets fall following appointment of RFK Jr as head of US Department of Health and Human Services in Trump administration.

Since September 2023, GSK's RSV vaccine has been approved in Japan for adults aged 60 and over. The regulatory expansion was supported by results from a global phase III trial. The company noted that, ...

AnaptysBio’s drug candidates rosnilimab and ANB032 hold key trial results ahead. Find out why ANAB stock is impacted by ...

Samsung Biologics has announced another significant manufacturing agreement, securing a $668m contract with a Europe-based ...

Recognizing that the available participant population for rare disease studies is often extremely limited and dispersed globally, GSK welcomed an innovative approach to expanding trial access—one that ...